KR20140061349A - Oral bacteria proliferation inhibitor - Google Patents
Oral bacteria proliferation inhibitor Download PDFInfo
- Publication number
- KR20140061349A KR20140061349A KR1020147001513A KR20147001513A KR20140061349A KR 20140061349 A KR20140061349 A KR 20140061349A KR 1020147001513 A KR1020147001513 A KR 1020147001513A KR 20147001513 A KR20147001513 A KR 20147001513A KR 20140061349 A KR20140061349 A KR 20140061349A
- Authority
- KR
- South Korea
- Prior art keywords
- sorbitol
- galactose
- bacteria
- oral cavity
- growth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 32
- 230000035755 proliferation Effects 0.000 title abstract description 19
- 239000003112 inhibitor Substances 0.000 title description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 47
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 47
- 239000000600 sorbitol Substances 0.000 claims abstract description 47
- 229930182830 galactose Natural products 0.000 claims abstract description 46
- 210000000214 mouth Anatomy 0.000 claims abstract description 22
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 21
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 19
- 230000012010 growth Effects 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 241000605986 Fusobacterium nucleatum Species 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 5
- 244000052769 pathogen Species 0.000 claims description 3
- 230000003239 periodontal effect Effects 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 150000005846 sugar alcohols Chemical class 0.000 abstract description 5
- 230000037406 food intake Effects 0.000 abstract description 2
- 229960002920 sorbitol Drugs 0.000 description 43
- 239000002609 medium Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010006326 Breath odour Diseases 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229960003082 galactose Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 235000013599 spices Nutrition 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 208000002925 dental caries Diseases 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 150000003464 sulfur compounds Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- SWMBOMMGMHMOHE-QQLCCCKISA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO SWMBOMMGMHMOHE-QQLCCCKISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 240000000298 Elaeagnus multiflora Species 0.000 description 1
- 235000009245 Elaeagnus multiflora Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- UPVAPSGKXAAHBG-CKTDUXNWSA-N [(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl n-[(2s,3r)-2-amino-3-hydroxybutanoyl]sulfamate Chemical compound O[C@@H]1[C@H](O)[C@@H](COS(=O)(=O)NC(=O)[C@@H](N)[C@H](O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 UPVAPSGKXAAHBG-CKTDUXNWSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- -1 sucrose fatty acid ester Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
- A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
- A23L9/10—Puddings; Dry powder puddings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Confectionery (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
구강 내 세균의 증식을 억제하는, 섭취해도 해가 없는 물질을 제공하는 것. 특히, 당과 당알코올을 병용했을 경우의 유용성에 대해서는 아직 밝혀지지는 않았으며, 구강 내 세균의 증식을 억제하는 당과 당알코올의 조합을 제공하는 것. 갈락토오스 및 소르비톨을 함유하는 것을 특징으로 하는 구강 내 세균의 증식 억제제. 본 발명에 관련된 구강 내 세균의 증식 억제제는 치주병의 개선 및 예방에 유효하다.Providing a substance that inhibits the proliferation of bacteria in the oral cavity and is free from ingestion or harm. Especially, the usefulness of the combination of sugar and sugar alcohol has not yet been clarified, and it is intended to provide a combination of sugar and sugar alcohol which inhibits the growth of bacteria in the oral cavity. The agent for inhibiting the growth of bacteria in the oral cavity, which comprises galactose and sorbitol. The agent for inhibiting the growth of bacteria in the oral cavity according to the present invention is effective for the improvement and prevention of periodontal disease.
Description
본 발명은 구강 내 세균의 증식 억제제에 관한 것이다.The present invention relates to an agent for inhibiting the growth of bacteria in the oral cavity.
인간의 구강 내에는 수백 종에 이르는 세균이 생식하고 있다고 알려져 있다. 이들 중에는, 잇몸이나 치주에 염증을 일으키거나, 산을 생산하여 뼈나 치아를 녹이거나 함으로써, 치주병이나 우식의 원인이 되는 균도 많이 포함된다.Hundreds of bacteria are known to reproduce in human oral cavity. Among these are many bacteria that cause periodontal disease or caries by causing irritation to gums and periodontal disease, or by producing acids to dissolve bones and teeth.
Fusobacterium nucleatum (이후 F. nucleatum) 은, 인간에 있어서, 정상·병증 부위의 양방의 플라크로부터 많이 검출되는 세균종이다 (비특허문헌 1, 2). 이 균은, 치주병의 진행과 함께 그 비율이 증가해 가는 점에서, 치주병의 발증과 진행에 기여하는 것으로 생각되고 있다 (비특허문헌 3 ∼ 5). 또, 다른 많은 세균과 부착하는 능력을 갖고 있으며, 덴탈 플라크 중에서, 조기 콜로니 형성 균종과 치주 병원균을 포함하는 후기 콜로니 형성 균종을 잇는 가교 역할을 담당하고 있는 것이 알려져 있다 (비특허문헌 6). 나아가서는, 구취의 원인 물질이 되는 휘발성 황화합물의 산생 균종이기도 하다 (비특허문헌 7). 따라서, F. nucleatum 에 대하여 활성을 나타내는 항균제는 치주병의 예방, 구강 내 세균의 감소, 및 구취의 예방, 저감에 유효한 것으로 생각된다.Fusobacterium nucleatum (hereinafter referred to as F. nucleatum) is a bacterium species that is frequently detected in plaques of both normal and diseased parts in humans (Non-Patent
이들 균을 활성화하거나, 또는 그 활성을 억제하거나 하는 물질에 대해서도 연구되고 있다. 예를 들어, 당류는 우식 원인균이 산을 만들 때의 원인 물질인 것이 널리 알려져 있다. 한편, 당알코올은 우식 원인균에 대한 증식 억제 작용을 갖는 것이 알려져 있고, 치주 병원균에 대한 증식 억제 작용도 최근 보고되고 있다.Materials for activating or inhibiting the activity of these bacteria have also been studied. For example, it is widely known that saccharides are causative agents of caries causing bacteria. On the other hand, it is known that sugar alcohols have a proliferation inhibitory action on carnivorous microorganisms, and the proliferation inhibitory action against periodontal pathogens is also recently reported.
치주 병원균이나 우식 병원균으로는 복수의 구강 내 세균이 알려져 있고, 그들 균의 증식을 억제하는 물질의 제공이 요구되고 있다. 또, 그러한 물질로는, 구강 내에서 작용하는 점에서, 체내에 섭취해도 해가 없는 물질인 것이 바람직하다.As a periodontal pathogen or a caries pathogen, a plurality of oral bacteria are known, and it is required to provide a substance that inhibits the proliferation of the bacteria. It is preferable that such a substance is a substance which is harmless even if taken into the body, in view of its action in the oral cavity.
상기 과제를 감안하여, 본 발명은 구강 내 세균의 증식을 억제하는, 섭취해도 해가 없는 물질을 제공하는 것을 그 목적으로 한다. 특히, 당과 당알코올을 병용했을 경우의 유용성에 대해서는 아직 밝혀지지는 않았으며, 구강 내 세균의 증식을 억제하는 당과 당알코올의 조합을 제공하는 것을 그 목적으로 한다.In view of the above problems, it is an object of the present invention to provide a substance that inhibits the proliferation of bacteria in the oral cavity and has no harmful effect on ingestion. Particularly, the usefulness of a combination of a sugar and a sugar alcohol has not yet been clarified. It is an object of the present invention to provide a combination of a sugar and a sugar alcohol which inhibits the growth of bacteria in the oral cavity.
본 발명자들은 예의 연구의 결과, 갈락토오스 및 소르비톨을 함유하는 배지에 있어서 구강 내 세균 F. nucleatum 의 증식이 현저하게 저해되는 것을 알아내고, 그것에 의해 본 발명을 완성시켰다. 즉, 본 발명은 갈락토오스 및 소르비톨을 함유하는 것을 특징으로 하는, 구강 내 세균의 증식 억제제에 관한 것이다.As a result of intensive studies, the inventors of the present invention have found that proliferation of bacterial F. nucleatum in oral cavity is remarkably inhibited in a culture medium containing galactose and sorbitol, thereby completing the present invention. That is, the present invention relates to an agent for inhibiting the growth of bacteria in the oral cavity, which comprises galactose and sorbitol.
본 발명에 관련된 구강 내 세균의 증식 억제제는, 식품 또는 구강 조성물에 함유시킴으로써, 안전하게 일상적으로 이용 또는 섭취하는 것이 가능하고, 효율적으로 구강 내 세균을 감소시키고, 또한 치주병을 개선 및 예방할 수 있고, 나아가서는 구취를 예방, 저감시킬 수도 있다.The agent for inhibiting the growth of bacteria in the oral cavity according to the present invention can be safely used or ingested on a routine basis by being contained in a food or oral composition and can effectively reduce the bacteria in the oral cavity and also improve and prevent periodontal disease, It can also prevent and reduce bad breath.
도 1 은 실시예 2 에 있어서의 각 배지에 대하여 얻어진 OD 값을 나타내는 그래프이다.
도 2 는 실시예 3 에 있어서의 각 배지에 대하여 얻어진 OD 값을 나타내는 그래프이다.
도 3 은 실시예 4 에 있어서의 각 배지에 대하여 얻어진 OD 값을 나타내는 그래프이다.Fig. 1 is a graph showing OD values obtained for each medium in Example 2. Fig.
2 is a graph showing OD values obtained for each medium in Example 3. Fig.
Fig. 3 is a graph showing OD values obtained for each medium in Example 4. Fig.
본 발명의 갈락토오스와 소르비톨을 함유하는 구강 내 세균의 증식 억제제는 F. nucleatum 의 증식을 상승적으로 억제하는 효과를 갖는다. F. nucleatum 은 다른 많은 세균과 부착함으로써 덴탈 플라크를 형성하는 원인이 되기 때문에, 이 균의 증식을 억제함으로써, 치주병이나 우식의 원인이 되는 구강 내의 다른 세균의 증식을 억제할 수 있다. 또, F. nucleatum 은 치주병의 병원균의 하나이므로, 본 발명은 치주병의 개선 및 예방에 유용하다. 나아가서는, 이 균은 구취의 원인 물질이 되는 휘발성 황화합물을 산생하므로, F. nucleatum 의 증식을 억제하는 것은 구취의 예방, 저감에도 유효한 것으로 생각된다.The agent for inhibiting the growth of bacteria in oral cavity containing galactose and sorbitol of the present invention has an effect of synergistically inhibiting the proliferation of F. nucleatum. Because F. nucleatum causes dental plaque formation by adhering to many other bacteria, it can inhibit the growth of other bacteria in the oral cavity, which causes periodontal disease and caries, by inhibiting the proliferation of this bacterium. In addition, since F. nucleatum is one of pathogenic bacteria of periodontal disease, the present invention is useful for improvement and prevention of periodontal disease. Furthermore, this bacterium produces volatile sulfur compounds that cause bad breath, so inhibiting the proliferation of F. nucleatum is considered to be effective for prevention and reduction of bad breath.
갈락토오스와 소르비톨의 합계 몰 농도는 0.5 M 이상 0.9 M 이하인 것이 바람직하다. 또, 갈락토오스와 소르비톨의 몰 농도의 비율은 갈락토오스 : 소르비톨 = 2 : 1 ∼ 1 : 3 인 것이 바람직하다.The total molar concentration of galactose and sorbitol is preferably 0.5 M or more and 0.9 M or less. The molar concentration of galactose and sorbitol is preferably in a molar ratio of galactose to sorbitol of 2: 1 to 1: 3.
본 발명에 있어서의 갈락토오스로는, β-D-갈락토오스를 사용하는 것이 바람직하다. 또, 본 발명에 있어서의 소르비톨로는, D-소르비톨 (D-소르비트) 을 사용하는 것이 바람직하다.As the galactose in the present invention, it is preferable to use? -D-galactose. As the sorbitol in the present invention, D-sorbitol (D-sorbitol) is preferably used.
또, 본 발명의 증식 억제제는 함수제, 치약, 흡입제 및 트로치제 등의 구강 조성물, 추잉검, 캔디, 정과, 구미젤리, 초콜릿, 비스킷 및 스낵 등의 과자, 아이스크림, 셔벗 및 빙과 등의 냉과, 음료, 빵, 핫케이크, 유제품, 햄 및 소시지 등의 축육 제품류, 또는 어묵 및 치쿠와 등의 어육 제품, 총채류, 푸딩, 수프 혹은 잼 등의 음식품에 배합하여 이용하는 것이 가능하다.In addition, the proliferation inhibitor of the present invention can be used for oral compositions such as a moisturizer, a toothpaste, an inhalant and a troche, a confectionery such as a chewing gum, a candy, a jelly, a jelly, a chocolate, a biscuit and a snack, It can be used in combination with beverages such as beverages, breads, hot cakes, dairy products, ham and sausage products, fish meat products such as fish cake and chikuwa, whole foods, puddings, soups or jams.
실시예 1Example 1
시료sample
D(+)-갈락토오스 (와코 쥰야쿠 : 특급), D(-)-소르비톨 (와코 쥰야쿠 : 1 급) 을 사용하였다.D (+) - galactose (Wako Pure Chemical Industries, Ltd.) and D (-) - sorbitol (Wako Pure Chemical Industries, Ltd.) were used.
공시 균주Published strain
구강 내 세균으로서 F. nucleatum JCM12990 주를 사용하였다.F. nucleatum JCM12990 strain was used as oral bacteria.
배지badge
Yeast extract (3.0 g/ℓ), Hemin (5.0 ㎎/ℓ), Menadione (0.5 ㎎/ℓ) 을 첨가한 Tripticase soy broth (이후 TSB 배지) 를 사용하여, 37 ℃ 의 혐기 조건하 (10 % CO2, 10 % H2, 80 % N2) 에서 배양하였다. 갈락토오스 또는 소르비톨, 혹은 갈락토오스 또한 소르비톨을 함유하는 배지에 대해서는, 7.0 ㎖ 의 TSB 배지에 3.0 ㎖ 첨가했을 때의 최종 농도가 설정 농도가 되도록, 갈락토오스, 소르비톨을 용해시킨 TSB 배지를 조제하였다. 모든 배지에 대하여, 필터 (ADVANTEC, 공경 0.20 ㎛) 멸균을 실시하였다.Yeast extract (3.0 g / ℓ) , Hemin (5.0 ㎎ / ℓ), Menadione (0.5 ㎎ / ℓ) a Tripticase soy broth (after TSB medium), anaerobic conditions, and (10% CO 2 at 37 ℃ using the addition of They were cultured in 10% H 2, 80% N 2). For medium containing galactose or sorbitol, or galactose or sorbitol, TSB medium in which galactose and sorbitol were dissolved was prepared so that the final concentration when 3.0 ml was added to 7.0 ml of TSB medium was the set concentration. All the media were sterilized by a filter (ADVANTEC, pore size 0.20 mu m).
균수의Bacterium 측정 Measure
구강 내 세균 F. nucleatum JCM12990 의 전 (前) 배양액을 TSB 배지 7.0 ㎖ 에 첨가하고, 대수 증식기까지 배양하였다. 전배양액 첨가시와 등량의 배양액을 제거하고, 일단 액량을 7.0 ㎖ 로 한 후, 10.0 ㎖ 중의 농도가 설정 농도가 되도록 조제한 갈락토오스, 소르비톨, 또는 갈락토오스와 소르비톨을 함유하는 TSB 배지 3.0 ㎖ 를 첨가하였다. 그 때, 갈락토오스 및 소르비톨 중 어느 것도 함유하지 않는 통상적인 배지 3.0 ㎖ 를 첨가한 것을 컨트롤로 하였다. 이들을 혐기 조건에서 1 시간 배양 후, 배양 시험관을 소형 진탕 배양 장치 (아드반텍 동양 주식회사 바이오 포토 리코더 TVS062CA) 내에 옮기고, 37 ℃ 에서 24 시간 배양 후, 파장 660 ㎚ 에서 광학 농도 (optical density : 이후 OD 값) 의 측정 (HITACHI U-3900H Spectrophotometer) 을 실시하였다.The pre-culture of oral bacteria F. nucleatum JCM12990 was added to 7.0 ml of TSB medium and cultured to logarithmic growth phase. The same amount of the culture medium as that of the previous culture medium was removed, and once the volume of the culture medium was adjusted to 7.0 ml, 3.0 ml of a TSB medium containing galactose, sorbitol or galactose and sorbitol prepared so as to have a predetermined concentration in 10.0 ml was added. At that time, 3.0 ml of a normal medium containing neither galactose or sorbitol was added to control the medium. After culturing them in the anaerobic condition for 1 hour, the culture tube was transferred into a small shaking culture apparatus (Biophotoreater TVS062CA, Advanetek TYOYANG Co., Ltd.), and cultured at 37 ° C for 24 hours. Optical density at OD 660 nm ) (HITACHI U-3900H Spectrophotometer).
실시예 2Example 2
실시예 1 에 있어서, 0.1 M 또는 0.6 M 의 갈락토오스를 함유하는 갈락토오스 첨가 TSB 배지, 0.2 M, 0.3 M 또는 0.6 M 의 소르비톨을 함유하는 소르비톨 첨가 TSB 배지, 상기 0.4 M 의 갈락토오스 및 0.2 M 의 소르비톨, 0.3 M 의 갈락토오스 및 0.3 M 의 소르비톨, 또는 0.3 M 의 갈락토오스 및 0.6 M 의 소르비톨을 함유하는 혼합 첨가 TSB 배지, 그리고 컨트롤을 준비하여 시험을 실시하였다. 각각의 TSB 배지에 대하여 얻어진 OD 값을 도 1 에 나타낸다. 0.1 M 또는 0.6 M 의 갈락토오스를 함유하는 TSB 배지에서 24 시간 배양한 결과, OD 값은 컨트롤의 OD 값을 크게 웃돌았다. F. nucleatum 은 갈락토오스를 대사하는 것이 보고되어 있고 (비특허문헌 8 ∼ 10), 그 영향으로 증식이 촉진된 것으로 추측된다. 또, 0.2 M, 0.3 M 또는 0.6 M 의 소르비톨을 함유하는 TSB 배지에서 각각 24 시간 배양했을 때, 0.2 M 에서는 컨트롤을 웃도는 OD 값, 0.3 M 에서는 컨트롤과 동 정도의 OD 값, 0.6 M 에서는 컨트롤을 밑도는 OD 값이 확인되었다.In Example 1, a TSB medium supplemented with galactose containing 0.1 M or 0.6 M of galactose, a TSB supplemented with sorbitol containing 0.2 M, 0.3 M or 0.6 M sorbitol, 0.4 M of galactose and 0.2 M of sorbitol, Mixed TSB medium containing 0.3 M of galactose and 0.3 M of sorbitol, 0.3 M of galactose and 0.6 M of sorbitol, and control were prepared and tested. The OD values obtained for each TSB medium are shown in Fig. When cultured in TSB medium containing 0.1 M or 0.6 M of galactose for 24 hours, the OD value exceeded the control OD value. It has been reported that F. nucleatum metabolizes galactose (Non-patent Documents 8-10), and it is presumed that the effect of F. nucleatum is promoted by the effect of F. nucleatum. When cultured in TSB medium containing 0.2 M, 0.3 M or 0.6 M sorbitol for 24 hours each, OD value exceeding control at 0.2 M, OD value at the same level as control at 0.3 M, control at 0.6 M The lower OD value was confirmed.
여기서, 증식의 촉진이 예상되는 0.4 M 의 갈락토오스와 증식의 촉진이 확인된 0.2 M 의 소르비톨을 함유하는 혼합 첨가 TSB 배지에서 24 시간 배양한 결과, 컨트롤을 밑도는 OD 값이 확인되었다. 동일하게, 0.3 M 갈락토오스와 0.3 M 소르비톨, 및 0.3 M 갈락토오스와 0.6 M 소르비톨을 함유하는 배지 조건에 대해서도, 컨트롤을 밑도는 OD 값이 확인되며, 이 값은 0.3 M 소르비톨, 0.6 M 소르비톨 단독 조건에서의 값보다 낮았다.Here, an OD value lower than the control was confirmed by culturing for 24 hours in a mixed-addition TSB medium containing 0.4 M of galactose, which is expected to promote proliferation, and 0.2 M of sorbitol, which has been confirmed to promote proliferation. Likewise, the OD value under control was also confirmed for medium containing 0.3 M galactose, 0.3 M sorbitol, 0.3 M galactose and 0.6 M sorbitol, and this value was found to be 0.3 M sorbitol, 0.6 M sorbitol Value.
이상의 결과로부터, 갈락토오스와 소르비톨을 배지에 함유시킴으로써, F. nucleatum 의 증식이 억제되는 것이 확인되었다.From the above results, it was confirmed that the proliferation of F. nucleatum was inhibited by containing galactose and sorbitol in the medium.
실시예 3Example 3
실시예 2 로부터, 갈락토오스와 소르비톨을 함께 배지에 첨가했을 때에 F. nucleatum 의 증식 억제 효과가 확인되었으므로, 이 효과가 확인되는 갈락토오스와 소르비톨의 비율을 변경하여, 동일한 증식 억제 효과가 확인되는지를 검토하였다. 또한, 갈락토오스와 소르비톨의 합계 몰 농도는 0.6 M 으로 설정하였다. 각각의 TSB 배지에 대하여 얻어진 OD 값을 도 2 에 나타낸다.From Example 2, it was confirmed that when galactose and sorbitol were added together to the medium, the proliferation inhibitory effect of F. nucleatum was confirmed, it was examined whether the same proliferation inhibitory effect was confirmed by changing the ratio of galactose and sorbitol in which this effect was confirmed . The total molar concentration of galactose and sorbitol was set to 0.6 M. The OD values obtained for each TSB medium are shown in Fig.
그 결과, 갈락토오스 : 소르비톨 = 2 : 1, 1 : 1, 1 : 2, 1 : 3 의 각 비율 조건에서, 컨트롤을 밑도는 OD 값이 확인되었다. 증식 억제의 정도는 갈락토오스 또는 소르비톨 중 어느 농도에도 의존하지 않으며, 갈락토오스 : 소르비톨 = 1 : 2 (갈락토오스 : 소르비톨 = 0.2 M : 0.4 M) 의 조건에서, 가장 강한 증식 억제 효과가 확인되었다.As a result, the OD value under control was confirmed under the conditions of the ratio of galactose: sorbitol = 2: 1, 1: 1, 1: 2, and 1: The degree of inhibition of proliferation was not dependent on any concentration of galactose or sorbitol, and the strongest inhibitory effect was confirmed under the conditions of galactose: sorbitol = 1: 2 (galactose: sorbitol = 0.2 M: 0.4 M).
실시예 4Example 4
실시예 3 에 있어서 가장 강한 증식 억제 효과가 확인된 갈락토오스 : 소르비톨 = 1 : 2 의 조건에 대하여, 비율은 그대로 두고, 합계 몰 농도를 변경하여 동일한 시험을 실시하였다. 각각의 TSB 배지에 대하여 얻어진 OD 값을 도 3 에 나타낸다.The same test was conducted under the conditions of galactose: sorbitol = 1: 2, in which the strongest proliferation inhibitory effect was confirmed in Example 3, while changing the total molar concentration while maintaining the ratio. The OD values obtained for each TSB medium are shown in Fig.
그 결과, 합계 몰 농도가 0.3 M, 0.4 M 인 조건에 대해서는, 컨트롤을 웃도는 OD 값이 확인되었다. 한편, 합계 몰 농도가 0.5 M, 0.6 M, 0.9 M 인 조건 에 대해서는, 컨트롤을 밑도는 OD 값이 확인되었다. 증식 억제의 정도는 합계 몰 농도에 의존적이지 않으며, 0.6 M (갈락토오스 : 소르비톨 = 0.2 M : 0.4 M) 의 조건에서, 가장 강한 증식 억제 효과가 확인되었다.As a result, OD values exceeding the control were confirmed for the conditions in which the total molar concentrations were 0.3 M and 0.4 M, respectively. On the other hand, for the conditions in which the total molar concentrations were 0.5 M, 0.6 M, and 0.9 M, OD values lower than the control were confirmed. The degree of inhibition of proliferation was not dependent on the total molar concentration, and the strongest proliferation inhibitory effect was confirmed under the conditions of 0.6 M (galactose: sorbitol = 0.2 M: 0.4 M).
실시예 5Example 5
본 실시예 이하에 본 발명에 의한 대표적인 배합예를 나타내지만, 본 발명은 이들에 한정되는 것은 아니다.Examples Hereinafter, typical formulation examples according to the present invention are shown, but the present invention is not limited thereto.
하기 처방에 따라 함수제를 제조하였다.The hydraulic agent was prepared according to the following formulation.
에탄올 2.0 중량%2.0% by weight of ethanol
향료 1.0Spice 1.0
갈락토오스 3.7Galactose 3.7
소르비톨 7.4Sorbitol 7.4
물 나머지Water rest
100.0100.0
실시예 6Example 6
하기 처방에 따라 치약을 제조하였다.The toothpaste was prepared according to the following prescription.
탄산칼슘 40.0 중량%Calcium carbonate 40.0 wt%
글리세린 10.0Glycerin 10.0
카르복시메틸셀룰로오스 2.0Carboxymethylcellulose 2.0
라우릴황산나트륨 2.0Sodium lauryl sulfate 2.0
향료 1.0Spice 1.0
사카린 0.1Saccharin 0.1
클로르헥시딘 0.01Chlorhexidine 0.01
갈락토오스 5.5Galactose 5.5
소르비톨 11.0Sorbitol 11.0
물 나머지Water rest
100.0100.0
실시예 7Example 7
하기 처방에 따라 구취용 스프레이를 제조하였다.A breath spray was prepared according to the following prescription.
에탄올 10.0 중량%Ethanol 10.0 wt%
글리세린 5.0Glycerin 5.0
향료 0.05Fragrance 0.05
착색료 0.001Coloring matter 0.001
갈락토오스 5.5Galactose 5.5
소르비톨 11.0Sorbitol 11.0
물 나머지Water rest
100.0100.0
실시예 8Example 8
하기 처방에 따라 트로치를 제조하였다.Troches were prepared according to the following prescription.
아라비아검 6.0 중량%Arabic gum 6.0 wt%
파라티니트 75.8Paramount 75.8
향료 1.0Spice 1.0
갈락토오스 5.5Galactose 5.5
소르비톨 11.0Sorbitol 11.0
모노플루오로인산나트륨Sodium monofluorophosphate 0.7 0.7
100.0100.0
실시예 9Example 9
하기 처방에 따라 추잉검을 제조하였다.The gum was prepared according to the following prescription.
검 베이스 20.0 중량%Gum base 20.0 wt%
파라티니트 61.5Paratunit 61.5
갈락토오스 5.5Galactose 5.5
소르비톨 11.0Sorbitol 11.0
향료 2.0Spice 2.0
100.0100.0
실시예 10Example 10
하기 처방에 따라 캔디를 제조하였다.Candies were prepared according to the following prescription.
환원 물엿 34.0 중량%Reduced starch syrup 34.0 wt%
파라티니트 33.5Paratiunit 33.5
시트르산 2.0Citric acid 2.0
향료 0.2Fragrance 0.2
갈락토오스 5.5Galactose 5.5
소르비톨 11.0Sorbitol 11.0
물 나머지Water rest
100.0100.0
실시예 11Example 11
하기 처방에 따라 정과를 제조하였다.The tablets were prepared according to the following prescription.
자당 지방산 에스테르 0.2 중량%0.2% by weight of sucrose fatty acid ester
파라티니트 78.6Paratyite 78.6
향료 0.2Fragrance 0.2
갈락토오스 5.5Galactose 5.5
소르비톨 11.0Sorbitol 11.0
물 4.5Water 4.5
100.0100.0
실시예 12Example 12
하기 처방에 따라 구미젤리를 제조하였다.Gumi jelly was prepared according to the following prescription.
젤라틴 60.0 중량%Gelatin 60.0 wt%
환원 물엿 21.6Reduced starch syrup 21.6
식물 유지 4.5Plant Maintenance 4.5
말산 2.0Malic acid 2.0
갈락토오스 3.8Galactose 3.8
소르비톨 7.6Sorbitol 7.6
향료 0.5Fragrance 0.5
100.0100.0
실시예 13Example 13
하기 처방에 따라 음료를 제조하였다.The beverage was prepared according to the following prescription.
오렌지 과즙 30.0 중량%Orange juice 30.0 wt%
시트르산 0.1Citric acid 0.1
비타민 C 0.04Vitamin C 0.04
향료 0.1Fragrance 0.1
갈락토오스 5.0Galactose 5.0
소르비톨 10.0Sorbitol 10.0
물 나머지Water rest
100.0100.0
이 출원은 2011년 6월 30일에 출원된 일본 특허 출원 제2011-145737호로부터의 우선권을 주장하는 것이며, 그 내용을 인용하여 이 출원의 일부로 하는 것이다.This application claims priority from Japanese Patent Application No. 2011-145737, filed on June 30, 2011, which is hereby incorporated by reference in its entirety.
Claims (7)
갈락토오스 및 소르비톨을 합계하여 0.5 M ∼ 0.9 M 의 농도로 함유하는 것을 특징으로 하는 구강 내 세균의 증식 억제제.The method according to claim 1,
Galactose, and sorbitol in a concentration of 0.5 M to 0.9 M in total.
갈락토오스 : 소르비톨의 비율은 2 : 1 ∼ 1 : 3 의 범위인 것을 특징으로 하는 구강 내 세균의 증식 억제제.3. The method according to claim 1 or 2,
Wherein the ratio of galactose to sorbitol is in the range of 2: 1 to 1: 3.
구강 내 세균은 치주 병원균인 것을 특징으로 하는 구강 내 세균의 증식 억제제.4. The method according to any one of claims 1 to 3,
The agent for inhibiting the growth of bacteria in the oral cavity, wherein the bacteria in the oral cavity are periodontal pathogens.
구강 내 세균은 Fusobacterium nucleatum 인 것을 특징으로 하는 구강 내 세균의 증식 억제제.5. The method according to any one of claims 1 to 4,
Wherein the bacterium in the oral cavity is Fusobacterium nucleatum.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011145737A JP2013010724A (en) | 2011-06-30 | 2011-06-30 | Oral bacteria proliferation inhibitor |
JPJP-P-2011-145737 | 2011-06-30 | ||
PCT/JP2012/004187 WO2013001817A1 (en) | 2011-06-30 | 2012-06-28 | Oral bacteria proliferation inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20140061349A true KR20140061349A (en) | 2014-05-21 |
Family
ID=47423736
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020147001513A Withdrawn KR20140061349A (en) | 2011-06-30 | 2012-06-28 | Oral bacteria proliferation inhibitor |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2013010724A (en) |
KR (1) | KR20140061349A (en) |
CN (1) | CN104039304A (en) |
TW (1) | TW201313234A (en) |
WO (1) | WO2013001817A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016048007A1 (en) * | 2014-09-24 | 2016-03-31 | 서울대학교 산학협력단 | Quorum sensing inhibitor containing d-galactose |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3466403T3 (en) * | 2017-10-04 | 2025-02-10 | PRISMAN GmbH | The use of monosaccharide for subgingival and/or supragingival tooth cleaning |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3816522A1 (en) * | 1988-05-14 | 1989-01-12 | Biodyn Ag | PROTECTIVE AGAINST CARIES |
US7189351B2 (en) * | 2001-10-25 | 2007-03-13 | Spherix Incorporated | D-tagatose as an anti-biofilm agent |
WO2006035821A1 (en) * | 2004-09-29 | 2006-04-06 | Kao Corporation | Composition for oral cavity |
JP2006182692A (en) * | 2004-12-27 | 2006-07-13 | Kao Corp | Oral composition |
JP2008303188A (en) * | 2007-06-08 | 2008-12-18 | Univ Of Tokushima | Candida biofilm remover |
-
2011
- 2011-06-30 JP JP2011145737A patent/JP2013010724A/en active Pending
-
2012
- 2012-06-28 KR KR1020147001513A patent/KR20140061349A/en not_active Withdrawn
- 2012-06-28 CN CN201280032036.7A patent/CN104039304A/en active Pending
- 2012-06-28 WO PCT/JP2012/004187 patent/WO2013001817A1/en active Application Filing
- 2012-06-29 TW TW101123499A patent/TW201313234A/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016048007A1 (en) * | 2014-09-24 | 2016-03-31 | 서울대학교 산학협력단 | Quorum sensing inhibitor containing d-galactose |
US10292993B2 (en) | 2014-09-24 | 2019-05-21 | Seoul National University R&Db Foundation | Method of inhibiting quorum sensing using D-galactose |
Also Published As
Publication number | Publication date |
---|---|
CN104039304A (en) | 2014-09-10 |
WO2013001817A1 (en) | 2013-01-03 |
TW201313234A (en) | 2013-04-01 |
JP2013010724A (en) | 2013-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2388457C2 (en) | Breath refresher for disinfecting oral cavity and containing magnolia bark extract and surface active substance | |
JPH08502970A (en) | Antibacterial mouthwash | |
WO2005105126A1 (en) | Active oxygen eliminator and moisturizer containing wild watermelon extract | |
CA2998139C (en) | Synergistic antibacterial effects of magnolia bark extract and l-arginine, n-lauroyl ethyl ester on plaque biofilm | |
AU2016321383B2 (en) | Synergistic antibacterial effects of magnolia bark extract and L-arginine, N-alpha-lauroyl ethyl ester on salivary bacteria | |
JP2010018544A (en) | Antimicrobial agent, composition for oral cavity and denture cleanser | |
KR102008035B1 (en) | Oral composition | |
KR20140061349A (en) | Oral bacteria proliferation inhibitor | |
KR100492034B1 (en) | Antibacterial agent and oral composition for preventing and treating caries and periodontal disease containing panduratin derivatives | |
TWI511748B (en) | Oral care composition containing deoxysaccharide antimetabolites | |
JP2010168299A (en) | Antibacterial agent comprising shellac as effective ingredient and antibacterial composition comprising the same | |
KR20120042969A (en) | Bad breath-removing agent | |
KR20180055521A (en) | Composition for prevention or treatment of oral disease comprising icaritin | |
CN106279304A (en) | A kind of cinnamylaldehyde derivatives and application thereof | |
JP6921655B2 (en) | Protease inhibitors, biofilm formation inhibitors, and oral compositions | |
Sriram et al. | Effectiveness of green tea on oral health in children. | |
JP7169626B2 (en) | Oral composition for periodontal bacteria | |
JP6219458B2 (en) | Oral composition | |
JP2023102536A (en) | oral care agent | |
KR20190041800A (en) | Composition for prevention or treatment of oral disease comprising Casticin | |
KR20180072427A (en) | Composition for prevention or treatment of oral disease comprising extracts of Artemisiae Annuae and Bamboo salts | |
KR20180055524A (en) | Composition for prevention or treatment of oral disease comprising punicalagin | |
KR20180055523A (en) | Composition for prevention or treatment of oral disease comprising nitidine chloride | |
KR20180055525A (en) | Composition for prevention or treatment of oral disease comprising cynarin | |
KR20180055527A (en) | Composition for prevention or treatment of oral disease comprising eriodictyol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20140120 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PG1501 | Laying open of application | ||
PC1203 | Withdrawal of no request for examination | ||
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |